{"id":"rivaroxaban-bay59-7939","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Gastrointestinal bleeding"},{"rate":"1-5%","effect":"Hemorrhage"},{"rate":"1-2%","effect":"Thrombocytopenia"},{"rate":"1-2%","effect":"Anemia"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by selectively inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots. This mechanism of action is specific to the coagulation pathway and does not affect other physiological processes.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:30.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Deep vein thrombosis"},{"name":"Pulmonary embolism"},{"name":"Atrial fibrillation for stroke prevention"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT06193863","phase":"","title":"An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-06-18","conditions":"Prevention of Venous Thromboembolism, Congenital Heart Disease, Fontan Procedure","enrollment":61},{"nctId":"NCT05900388","phase":"","title":"A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-09-01","conditions":"Venous Thromboembolism, Children Under 2 Years","enrollment":850},{"nctId":"NCT06278051","phase":"","title":"An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-02-19","conditions":"Venous Thromboembolism","enrollment":320},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708},{"nctId":"NCT04174859","phase":"","title":"Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-12-10","conditions":"Non-valvular Atrial Fibrillation","enrollment":812},{"nctId":"NCT04356989","phase":"","title":"Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-05-13","conditions":"Non-valvular Atrial Fibrillation (NVAF)","enrollment":493},{"nctId":"NCT05150938","phase":"","title":"A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-03-18","conditions":"Treatment of Venous Thromboembolism in Cancer Patients","enrollment":5737},{"nctId":"NCT03455439","phase":"","title":"Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-03-16","conditions":"Heart Failure","enrollment":552},{"nctId":"NCT02864758","phase":"","title":"Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-08","conditions":"Atrial Fibrillation","enrollment":99999},{"nctId":"NCT02975453","phase":"","title":"Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-12-05","conditions":"Atrial Fibrillation","enrollment":1481},{"nctId":"NCT04401761","phase":"","title":"A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-05-28","conditions":"Coronary Artery Disease, Peripheral Artery Disease","enrollment":3189},{"nctId":"NCT05022758","phase":"","title":"A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-10-06","conditions":"Non-valvular Atrial Fibrillation (NVAF)","enrollment":45000},{"nctId":"NCT00839163","phase":"PHASE2","title":"Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Venous Thrombosis, Deep Vein Thrombosis","enrollment":613},{"nctId":"NCT01582737","phase":"","title":"Xarelto [SPAF] Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-05-30","conditions":"Brain Ischemia","enrollment":11310},{"nctId":"NCT03242278","phase":"","title":"Real-world Dosing Patterns of Rivaroxaban in the United States","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-12","conditions":"Atrial Fibrillation","enrollment":12507},{"nctId":"NCT05112666","phase":"","title":"A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-12-02","conditions":"Treatment of Venous Thromboembolism in Cancer Patients","enrollment":2601},{"nctId":"NCT04923139","phase":"","title":"A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-24","conditions":"Treatment of Venous Thromboembolism","enrollment":2627},{"nctId":"NCT01776424","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-28","conditions":"Prevention & Control","enrollment":27395},{"nctId":"NCT02558465","phase":"","title":"Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-11-13","conditions":"Venous Thromboembolism","enrollment":2540},{"nctId":"NCT05461807","phase":"","title":"An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-07-14","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism, Cancer","enrollment":2437},{"nctId":"NCT01606995","phase":"","title":"Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06-12","conditions":"Atrial Fibrillation","enrollment":6784},{"nctId":"NCT01442792","phase":"PHASE2","title":"Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10-12","conditions":"Cardiovascular Disease, Coronary Artery Disease","enrollment":108},{"nctId":"NCT04509193","phase":"","title":"A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-21","conditions":"Atrial Fibrillation","enrollment":116049},{"nctId":"NCT03746275","phase":"","title":"Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-11-13","conditions":"Atherosclerosis","enrollment":5798},{"nctId":"NCT03965741","phase":"","title":"Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-05-30","conditions":"Venous Thromboembolism (VTE)","enrollment":97765},{"nctId":"NCT03847181","phase":"","title":"Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-02-28","conditions":"Atrial Fibrillation","enrollment":45164},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT01907048","phase":"","title":"Patient and Physician Knowledge of Key Safety Messages","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-09-15","conditions":"Anticoagulation","enrollment":2227},{"nctId":"NCT04297072","phase":"","title":"Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-05-01","conditions":"Non-Valvular Atrial Fibrillation","enrollment":25000},{"nctId":"NCT04720092","phase":"PHASE1","title":"A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-05","conditions":"Thromboembolic Disorders","enrollment":30},{"nctId":"NCT03715725","phase":"","title":"A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.","status":"TERMINATED","sponsor":"Bayer","startDate":"2018-10-31","conditions":"Non-valvular Atrial Fibrillation","enrollment":70000},{"nctId":"NCT02504216","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-18","conditions":"Peripheral Artery Disease","enrollment":6564},{"nctId":"NCT03563937","phase":"","title":"Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-06-15","conditions":"Atrial Fibrillation","enrollment":64920},{"nctId":"NCT03284762","phase":"","title":"Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-11","conditions":"Atrial Fibrillation","enrollment":1216},{"nctId":"NCT03374540","phase":"","title":"Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-01","conditions":"Nonvalvular Atrial Fibrillation","enrollment":78517},{"nctId":"NCT03119116","phase":"","title":"Use of Direct Oral Anticoagulants in UK","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-15","conditions":"Stroke","enrollment":31336},{"nctId":"NCT02234843","phase":"PHASE3","title":"EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-11-13","conditions":"Venous Thromboembolism","enrollment":500},{"nctId":"NCT02556203","phase":"PHASE3","title":"Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-12-16","conditions":"Transcatheter Aortic Valve Replacement","enrollment":1653},{"nctId":"NCT03359876","phase":"","title":"Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-01","conditions":"Atrial Fibrillation","enrollment":16000},{"nctId":"NCT02111564","phase":"PHASE3","title":"A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-07","conditions":"Heart Failure, Respiratory Insufficiency, Stroke Acute","enrollment":12024},{"nctId":"NCT02210819","phase":"","title":"Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-06-27","conditions":"Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":1987},{"nctId":"NCT01598051","phase":"","title":"Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-05-31","conditions":"Non-valvular Atrial Fibrillation (NVAF)","enrollment":741},{"nctId":"NCT02497716","phase":"PHASE1","title":"Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-11-04","conditions":"Thrombosis","enrollment":47},{"nctId":"NCT02313909","phase":"PHASE3","title":"Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-12-23","conditions":"Stroke","enrollment":7213},{"nctId":"NCT02876718","phase":"","title":"Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-08-11","conditions":"Atrial Fibrillation","enrollment":253},{"nctId":"NCT03214172","phase":"","title":"Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-07-15","conditions":"Venous Thromboembolism","enrollment":1000},{"nctId":"NCT02309411","phase":"PHASE2","title":"EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-01-15","conditions":"Venous Thromboembolism","enrollment":46},{"nctId":"NCT02564718","phase":"PHASE1, PHASE2","title":"Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-11-19","conditions":"Thromboembolism","enrollment":10},{"nctId":"NCT03462446","phase":"","title":"Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-01","conditions":"Atrial Fibrillation","enrollment":249},{"nctId":"NCT02611635","phase":"","title":"Atrial Fibrillation Patient Preference Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-02","conditions":"Atrial Fibrillation","enrollment":382},{"nctId":"NCT02960880","phase":"","title":"Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-10-15","conditions":"Atrial Fibrillation","enrollment":99999},{"nctId":"NCT01750788","phase":"","title":"Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-01-13","conditions":"Atrial Fibrillation","enrollment":2297},{"nctId":"NCT01684423","phase":"PHASE2","title":"Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-19","conditions":"Venous Thrombosis","enrollment":64},{"nctId":"NCT02607371","phase":"","title":"Anticoagulation Preference by AF Patients Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-27","conditions":"Atrial Fibrillation","enrollment":198},{"nctId":"NCT01800006","phase":"","title":"Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-01-14","conditions":"Atrial Fibrillation","enrollment":2101},{"nctId":"NCT02690155","phase":"","title":"Real-world Comparative Effectiveness of Rivaroxaban Versus VKA","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-12","conditions":"Atrial Fibrillation","enrollment":38831},{"nctId":"NCT01400646","phase":"PHASE1","title":"A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Healthy","enrollment":46},{"nctId":"NCT01656330","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-07","conditions":"Healthy","enrollment":35},{"nctId":"NCT01205932","phase":"PHASE3","title":"Dose-confirmatory Bridging Study in Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-09","conditions":"Venous Thromboembolism","enrollment":402},{"nctId":"NCT01853800","phase":"PHASE1","title":"Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05","conditions":"Biological Availability","enrollment":14},{"nctId":"NCT01516814","phase":"PHASE3","title":"Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02","conditions":"Pulmonary Embolism","enrollment":40},{"nctId":"NCT01444586","phase":"","title":"Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":"Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee","enrollment":2293},{"nctId":"NCT01029743","phase":"","title":"Xarelto Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12","conditions":"Venous Thromboembolism","enrollment":3388},{"nctId":"NCT01619007","phase":"","title":"Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-06","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":5145},{"nctId":"NCT02262676","phase":"","title":"Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-10","conditions":"Atrial Fibrillation","enrollment":2251},{"nctId":"NCT01805544","phase":"","title":"Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05","conditions":"Venous Thrombosis","enrollment":113},{"nctId":"NCT00831714","phase":"","title":"Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-02","conditions":"Venous Thromboembolism","enrollment":19076},{"nctId":"NCT01925755","phase":"","title":"Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07","conditions":"Stroke, Embolism","enrollment":209},{"nctId":"NCT01855139","phase":"","title":"Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07","conditions":"Atrial Fibrillation","enrollment":106},{"nctId":"NCT01516840","phase":"PHASE3","title":"Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-03","conditions":"Deep Vein Thrombosis","enrollment":60},{"nctId":"NCT01805531","phase":"","title":"Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-04","conditions":"Atrial Fibrillation","enrollment":411},{"nctId":"NCT01206972","phase":"PHASE3","title":"Dose-confirmatory Bridging Study in Total Knee Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-10","conditions":"Venous Thromboembolism","enrollment":302},{"nctId":"NCT01855100","phase":"","title":"Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07","conditions":"Venous Thrombosis","enrollment":131},{"nctId":"NCT00571649","phase":"PHASE3","title":"Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Venous Thromboembolism","enrollment":8101},{"nctId":"NCT01839357","phase":"PHASE3","title":"Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-08","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT01523418","phase":"","title":"Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2014-10","conditions":"Prophylaxis, Thromboembolism, Venous, Total Knee Replacement, Total Hip Replacement","enrollment":""},{"nctId":"NCT00786422","phase":"PHASE2","title":"Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Venous Thrombosis, Deep Vein Thrombosis","enrollment":25},{"nctId":"NCT02485873","phase":"","title":"Real-Life Evidence on Stroke Prevention in SPAF","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-05","conditions":"Atrial Fibrillation (Prevention of Stroke)","enrollment":8607},{"nctId":"NCT02537405","phase":"PHASE1","title":"Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-02","conditions":"Embolism, Atrial Fibrillation and Venous Thrombosis","enrollment":40},{"nctId":"NCT02537457","phase":"PHASE1","title":"Bioequivalence Study of Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01","conditions":"Embolism, Atrial Fibrillation and Venous Thrombosis","enrollment":40},{"nctId":"NCT01145859","phase":"PHASE1","title":"Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-11","conditions":"Venous Thrombosis, Pediatrics","enrollment":59},{"nctId":"NCT02367027","phase":"PHASE1","title":"Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-02","conditions":"Pharmacokinetics","enrollment":18},{"nctId":"NCT01674647","phase":"PHASE3","title":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Atrial Fibrillation","enrollment":1504},{"nctId":"NCT01436526","phase":"PHASE1","title":"Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-08","conditions":"Therapeutic Equivalency","enrollment":28},{"nctId":"NCT00494871","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-06","conditions":"Atrial Fibrillation","enrollment":1280},{"nctId":"NCT01507051","phase":"PHASE1","title":"Switching Study From Warfarin to Rivaroxaban","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-11","conditions":"Venous Thrombosis","enrollment":96},{"nctId":"NCT00332020","phase":"PHASE3","title":"Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Prevention, Venous Thromboembolism","enrollment":2457},{"nctId":"NCT00973323","phase":"PHASE2","title":"BAY59-7939 Japanese in Atrial Fibrillation (2nd)","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-09","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT00973245","phase":"PHASE2","title":"BAY59-7939 in Atrial Fibrillation Once Daily (OD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-07","conditions":"Atrial Fibrillation","enrollment":102},{"nctId":"NCT00779064","phase":"PHASE2","title":"BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-07","conditions":"Atrial Fibrillation","enrollment":36},{"nctId":"NCT00402467","phase":"PHASE2","title":"An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-02","conditions":"Venous Thromboembolism","enrollment":613},{"nctId":"NCT00839826","phase":"PHASE2","title":"ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Thromboembolism, Prevention","enrollment":641},{"nctId":"NCT00439725","phase":"PHASE3","title":"Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-02","conditions":"Venous Thromboembolism","enrollment":1197},{"nctId":"NCT00362232","phase":"PHASE3","title":"Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-06","conditions":"Venous Thromboembolism","enrollment":3148},{"nctId":"NCT00396786","phase":"PHASE2","title":"Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-11","conditions":"Venous Thromboembolism","enrollment":877},{"nctId":"NCT00329628","phase":"PHASE3","title":"Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Venous Thromboembolism","enrollment":4541},{"nctId":"NCT00395772","phase":"PHASE2","title":"Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-12","conditions":"Venous Thromboembolism","enrollment":543}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rivaroxaban (BAY59-7939)","genericName":"Rivaroxaban (BAY59-7939)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade. Used for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}